Key terms
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TERN news
Apr 10
4:10pm ET
Terns Pharmaceuticals appoints Melita Sun Jung as chief business officer
Apr 04
2:48am ET
3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts
Apr 03
8:11am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Mar 29
4:26am ET
Buy Rating on Terns Pharmaceuticals Amid Promising Developments in Obesity Treatment Sector
Mar 27
7:04am ET
Terns Pharmaceuticals price target lowered to $18 from $19 at UBS
Mar 21
2:37am ET
Optimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stability
Mar 18
6:36am ET
Terns Pharmaceuticals price target lowered to $15 from $17 at JMP Securities
Mar 18
12:30am ET
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Mar 15
5:45pm ET
Optimistic Buy Rating for Terns Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
Mar 14
4:15pm ET
Terns Pharmaceuticals reports Q4 EPS (29c), consensus (29c)
Mar 11
4:21pm ET
Terns Pharmaceuticals receives orphan drug designation for TERN-701 from FDA
Mar 07
2:56pm ET
Terns treatment of chronic myelogenous leukemia granted orphan status
Mar 05
1:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 15
1:38am ET
Buy Rating Affirmed for Terns Pharmaceuticals Amid Positive Industry Outlook and Strategic Positioning
Feb 08
4:44am ET
Terns Pharmaceuticals Welcomes New CEO and Board Member
Feb 08
4:44am ET
Terns Pharmaceuticals Welcomes Amy Burroughs as CEO
Feb 07
8:21am ET
Terns Pharmaceuticals appoints Burroughs as CEO
Feb 05
4:31am ET
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Merck & Company (MRK) and Neurocrine (NBIX)
Jan 12
7:16am ET
Buy Rating on Terns Pharmaceuticals: Anticipated Clinical Milestones and Therapeutic Developments Signal Growth
No recent press releases are available for TERN
TERN Financials
Key terms
Ad Feedback
TERN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TERN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
